Hualan Vac(SZ:301207) Xin Lang Cai Jing·2025-11-17 02:35Core Insights - Hualan Biological Engineering experienced a 5% drop in stock price, trading at 24.11 CNY per share with a total market capitalization of 14.491 billion CNY as of November 17 [1] Company Overview - Hualan Biological Engineering Co., Ltd. is located in Xinxiang, Henan Province, established on November 9, 2005, and listed on February 18, 2022. The company primarily focuses on the research, production, and sales of human vaccines, with 98.11% of its revenue derived from vaccine products and 1.89% from other sources [1] Shareholder Analysis - Among the top ten circulating shareholders of Hualan Biological, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 8,700 shares in the third quarter, now holding 1.6522 million shares, which represents 0.28% of the circulating shares. The estimated floating loss today is approximately 2.0983 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. Year-to-date returns are 27.45%, ranking 1919 out of 4216 in its category, while the one-year return is 21.12%, ranking 2025 out of 3956. Since inception, the fund has returned 12.79% [2] - The fund manager, Cui Lei, has been in the position for 7 years and 12 days, managing assets totaling 122.76 billion CNY, with the best fund return during the tenure being 181.49% and the worst being -15.93% [2]